Reimbursement
Protecting Access to Medicare Act(PAMA)
In one line
Law that revised Medicare pricing for clinical lab services.
Definition
PAMA (2014) requires CMS to set Clinical Laboratory Fee Schedule rates based on weighted-median private payer rates reported by clinical labs. Repeated reporting and rate cuts have pressured the IVD industry.
Under PAMA, applicable labs report private payer rates, and CMS sets each test's payment at the weighted median. Congress has delayed the next reporting period and the scheduled cuts several times. PAMA also created the Advanced Diagnostic Laboratory Test category, with special payment rules for unique tests from a single lab.
Why it matters
Combined with FDA LDT oversight, PAMA reshapes molecular diagnostics economics.
Common pitfalls
- •A common pitfall is underestimating the administrative burden and technical complexities associated with accurate data collection and reporting of private payer rates to CMS.
- •Companies often fail to proactively model the financial impact of PAMA-driven rate reductions on their product portfolios and overall business strategy, leading to unexpected revenue losses.
- •Misinterpreting the definitions of "applicable laboratory" or "advanced diagnostic laboratory test" (ADLT) can lead to non-compliance with reporting requirements or incorrect payment methodologies.
- •Some organizations mistakenly believe that PAMA only affects clinical laboratories providing services, overlooking its downstream impact on IVD manufacturers whose products are used in those laboratories.
- •Failure to maintain robust internal processes for auditing reported data can result in inaccuracies, potentially leading to CMS recoupment actions or penalties.
Sources